Mirae Asset Global ETFs Holdings
FDMT icon

Mirae Asset Global ETFs Holdings’s 4D Molecular Therapeutics FDMT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
26,444
+635
+2% +$6.19K ﹤0.01% 2193
2026
Q1 		$237K Buy
25,809
+2,271
+10% +$19.8K ﹤0.01% 2274
2025
Q4 		$177K Buy
23,538
+4,638
+25% +$47K ﹤0.01% 2405
2025
Q3 		$164K Sell
18,900
-3,058
-14% -$18.3K ﹤0.01% 2431
2025
Q2 		$81.5K Sell
21,958
-4,482
-17% -$15.8K ﹤0.01% 2711
2025
Q1 		$85.4K Sell
26,440
-2,536
-9% -$11.9K ﹤0.01% 2699
2024
Q4 		$161K Sell
28,976
-1,975
-6% -$15.5K ﹤0.01% 2488
2024
Q3 		$335K Buy
30,951
+6,202
+25% +$103K ﹤0.01% 2112
2024
Q2 		$519K Buy
+24,749
New +$621K ﹤0.01% 1808

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Mirae Asset Global ETFs Holdings's FDMT Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its 4D Molecular Therapeutics (FDMT) stake by 2.5% in Q2 2026, buying an estimated $6.19K and bringing the position to 26,444 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #2193.

Mirae Asset Global ETFs Holdings first reported a position in FDMT in Q2 2024 and has held it in 9 quarters since. The position peaked at $519K in Q2 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 26,444 shares of 4D Molecular Therapeutics worth $349K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 635 4D Molecular Therapeutics shares in Q2 2026, an estimated $6.19K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2193 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in 4D Molecular Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's 4D Molecular Therapeutics position peaked at $519K in Q2 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.